Dulaglutide dosage: pens, doses and schedules
| Pen strength | Solution per pen | Source |
|---|---|---|
| 0.75 mg | 0.5 mL | US label1 |
| 1.5 mg | 0.5 mL | EU product information2 |
| 3 mg | 0.5 mL | EU product information2 |
| 4.5 mg | 0.5 mL | US label1 |
The US label gives an adult starting dosage of 0.75 mg injected subcutaneously once weekly; after 4 weeks the dosage may be increased to 1.5 mg once weekly for additional glycemic control, and then in 1.5 mg increments after at least 4 weeks on the current dosage, to a maximum of 4.5 mg once weekly.1
Pen strengths and form
The table is set at the top of the page
Dulaglutide is a clear solution in single-dose pens, four to a US carton.1 Both labels describe a ready solution in pens; the EU product information says that in the absence of compatibility studies it must not be mixed with other medicinal products, and searches of DailyMed, the EMA product information, PubMed and a trial registry found no label or human trial for a vial or powder form.12 The US package label marks each pen single-dose only and says each pen delivers its own dose, from 0.75 mg to 4.5 mg; a search of both labels found no syringe or U-100 instruction for the pen, and units and dosing covers syringes.1
Starting dose and steps
The EU product information gives adults 0.75 mg once weekly as monotherapy, which its indication limits to when metformin is considered inappropriate due to intolerance or contraindications, and 1.5 mg once weekly as add-on therapy; if needed, 1.5 mg can be increased after at least 4 weeks to 3 mg once weekly, and 3 mg after at least 4 weeks to 4.5 mg once weekly, the maximum.2
For pediatric patients 10 years of age and older with type 2 diabetes, the US label gives a starting dosage of 0.75 mg once weekly and, if additional glycemic control is needed, a maximum of 1.5 mg once weekly after at least 4 weeks.1 The US label lists glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes, and reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, and gives no weight-loss indication.1
Doses used in trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| AWARD-11 (Frias and colleagues, 2021)3 | Once weekly: dulaglutide 1.5, 3.0 or 4.5 mg, reached from 0.75 mg for 4 weeks with steps every 4 weeks43 | 612, 616 and 614 adults with type 2 diabetes on metformin4 | 52 weeks of treatment, 36‐week primary efficacy time point4 |
| AWARD-5 (Nauck and colleagues) | Dulaglutide 1.5 mg or 0.75 mg once weekly, against sitagliptin 100 mg once daily or placebo (placebo-controlled period up to 26 weeks)5 | 1,098 uncontrolled, metformin-treated patients with type 2 diabetes5 | 104-week treatment period, 52-week primary data5 |
| REWIND (Gerstein and colleagues, 2019) | Weekly subcutaneous injection: dulaglutide 1.5 mg or placebo6 | 9901 men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors (4949 dulaglutide, 4952 placebo)6 | Median follow-up 5.4 years6 |
| SUSTAIN 7 (Pratley and colleagues, 2018) | Once a week, open label: dulaglutide 0.75 mg or 1.5 mg, against semaglutide 0.5 mg or 1.0 mg7 | 1201 adults on metformin monotherapy randomised, 299 exposed to each dulaglutide dose7 | Primary endpoint at week 407 |
Giving it and missed doses
The US label says to give it once weekly, any time of day, with or without food, injected subcutaneously in the abdomen, thigh or upper arm, rotating injection sites with each dose.1 The US label and the EU product information both say a missed dose is given as soon as possible if at least 3 days (72 hours) remain until the next dose, and skipped if less than 3 days remain.12 Both texts say the weekly day can be changed, if necessary, as long as the last dose was given 3 or more days before.12
Storage
The US label says to store pens in the refrigerator at 2 to 8 °C (36 to 46 °F), not frozen and protected from light; if needed, each single-dose pen can be kept at room temperature not above 30 °C (86 °F) for a total of 14 days.1 The EU product information gives a shelf life of 2 years refrigerated at 2 to 8 °C, not frozen, in the original package to protect from light, and, in use, up to 14 days unrefrigerated at not above 30 °C.2
Frequently asked questions
What do Milligram users log for dulaglutide?
No dulaglutide share from Milligram's anonymous dose logs was large enough to show, so none is given.
Does the dose change with weight, age or injection site?
A population pharmacokinetic analysis by Geiser and colleagues (2016) in patients with type 2 diabetes reported that its findings suggest dose adjustment is not necessary on the basis of body weight, sex, age, race or ethnicity or site of injection.8 The US label says injection site had no statistically significant effect on exposure, and the EU product information says no dose adjustment is required based on age.12
References
- Eli Lilly and Company (DailyMed). These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY. TRULICITY (dulaglutide) injection, for subcutaneous use Initial U.S. Approval: 2014. 2026. dailymed.nlm.nih.gov
- European Medicines Agency. Trulicity, INN:dulaglutide. ema.europa.eu
- ClinicalTrials.gov. NCT03495102: A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes. 2020. clinicaltrials.gov
- Diabetes Obes Metab. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11. 2021. pmc.ncbi.nlm.nih.gov
- Diabetes Care. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). 2014. pmc.ncbi.nlm.nih.gov
- Lancet. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. 2019. pubmed.ncbi.nlm.nih.gov
- Lancet. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. 2018. pubmed.ncbi.nlm.nih.gov
- Clin Pharmacokinet. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. 2016. pubmed.ncbi.nlm.nih.gov